Pieris Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Comprehensive Income (Loss)

Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (9,849,964)us-gaap_NetIncomeLoss	$ 66,196us-gaap_NetIncomeLoss
Other comprehensive loss
Foreign currency translation adjustments	113,176	23,109
Total other comprehensive income (loss), after tax	113,176	23,109
Comprehensive income (loss) attributable to the owners of Pieris Pharmaceuticals, Inc.	$ (9,736,788)us-gaap_ComprehensiveIncomeNetOfTax	$ 89,305us-gaap_ComprehensiveIncomeNetOfTax

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

- Definition

Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References + Details